

S7 Table. Univariable and multivariable Cox survival analyses of pre- and perioperative predictors of overall survival using development set

Variable	Univariable		Multivariable	
	Hazard ratio	p-value	Hazard ratio	p-value
Clinical variable				
Age (yr)	0.99 (0.97-1.02)	0.659	-	-
Male sex	1.48 (0.92-2.35)	0.103	-	-
Serum CA19-9			-	-
Baseline (> 37 U/mL)	1.05 (0.63-1.74)	0.849	-	-
Response to neoadjuvant therapy (ref.: normalized)				
Not elevated	1.65 (0.89-3.07)	0.111	1.32 (0.67-2.53)	0.407
Not normalized, i.e., elevated preop. CA19-9	2.88 (1.65-5.05)	< 0.001	1.83 (1.01-3.32)	0.046
Serum CEA > 5 ng/mL				
Baseline	0.70 (0.40-1.23)	0.217	-	-
Preop.	1.01 (0.50-2.03)	0.974	-	-
Serum total bilirubin > 1.5 mg/dL				
Baseline	1.40 (0.89-2.21)	0.147	-	-
Preop.	1.45 (0.52-4.00)	0.475	-	-
Neoadjuvant therapy: no radiation	0.56 (0.24-1.30)	0.176	-	-
Interval from baseline CT to surgery (mo)	0.94 (0.88-1.00)	0.062	-	-
Pancreatectomy type: pancreaticoduodenectomy or total pancreatectomy	1.59 (0.82-3.09)	0.173	-	-
R1 resection	1.28 (0.74-2.22)	0.377	-	-
CT findings				
Tumor location: pancreatic head or neck	1.22 (0.66-2.27)	0.527	-	-
Tumor diameter				
Baseline (mm)	1.01 (0.99-1.03)	0.227	-	-
Any degree of change: stable or increase	3.37 (2.12-5.36)	< 0.001	3.10 (1.84-5.21)	< 0.001
Any degree of change in tumor-vessel relationship				
Increase in tumor: any artery contact	5.01 (2.06-12.22)	< 0.001	1.81 (0.68-4.81)	0.234
Increase in tumor: any vein contact or stenosis	2.86 (0.68-11.96)	0.150	-	-
Borderline resectable or locally advanced disease by NCCN criteria				
Baseline	1.39 (0.88-2.18)	0.155	-	-
Preop.	1.51 (0.96-2.38)	0.077	-	-
Presence of suspicious node				
Baseline	1.39 (0.88-2.18)	0.164	-	-
Preop.	1.64 (1.02-2.63)	0.040	1.54 (0.92-2.57)	0.101
Tumor invasion to stomach or duodenum				
Baseline	1.79 (1.10-2.91)	0.020	1.40 (0.42-4.70)	0.588
Preop.	2.24 (1.34-3.74)	0.002	1.46 (0.41-5.19)	0.559

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CT, computed tomography; preop., preoperative.